|Videos|October 24, 2022

Dr. Rana McKay on practice-changing trials in advanced renal cell carcinoma

Rana McKay, MD, says the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials have revolutionized the first-line treatment paradigm in advanced renal cell carcinoma.

Rana McKay, MD, describes the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials, which she says, “have largely changed the way we treat kidney cancer in the modern era for patients with advanced/metastatic disease.” McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME